Ignite Creation Date:
2024-05-06 @ 7:54 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02624570
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2020-07-15
First Post:
2015-12-03
Brief Title:
Midostaurin Access Program for Newly Diagnosed FLT3 ITD or TKD Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Sponsor:
Organization:
Novartis
Study Design
Study Type:
EXPANDED_ACCESS
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
True
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
None
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
Time Perspective List:
Who Masked List: